The European Patent Office has published patent application EP3464371A1, titled "BAFF-R TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELLS AND USES THEREOF." This publication, dated March 11, 2026, details advancements in CAR T-cell therapy targeting BAFF-R, with applicants including City of Hope and The University of Texas System.

This patent publication is primarily an informational notice regarding intellectual property. While it does not impose direct compliance obligations on regulated entities, it signifies potential future developments in the field of cancer immunotherapy. Companies involved in CAR T-cell research, development, or manufacturing should be aware of this publication as it pertains to patent landscapes and potential licensing or collaboration opportunities within the European Union.